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In this scientific advisory report on public health policy, the Superior Health Council of 
Belgium provides recommendations on the diagnosis of dementia, behaviour management 
and the ethical issues raised. 
 
This report aims at providing professionals with specific recommendations on the diagnosis of 
dementia, behaviour management and the ethical issues raised. 
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1 The Council reserves the right to make minor typographical amendments to this document at any time. On the other hand, 
amendments that alter its content are automatically included in an erratum. In this case, a new version of the advisory report is issued. 
2 The Council wishes to clarify that the MeSH terms and keywords are used for referencing purposes as well as to provide an easy 
definition of the scope of the advisory report. For more information, see the section entitled "methodology". 
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INTRODUCTION AND ISSUE 
In 2012, a WHO report on the world-wide issue of dementia ("Dementia: a public health priority") 
estimated that the number of cases of dementia will have tripled by 2050. The report also deplored 
the fact that only 20 to 50% of dementia cases are diagnosed, often too late. Hence the need for 
early diagnosis but also of raising public awareness of dementia-related disorders and of reducing 
the stigmatisation of patients. Indeed, the latter often face social isolation, which is linked to a lack 
of information on and understanding of dementia. Early care and the differential diagnosis also 
stand to benefit from a better knowledge of the first clinical signs.  Finally, special attention should 
also be paid to the providing of help to those with the illness and those taking care of them, the 
issue of residential care as well as healthcare staff training in long-term clinical care.  
Moreover, this is obviously an issue that concerns us all. The increased life-expectancy has had 
as a corollary that the number of age-related diseases too is on the rise. Also, this is an issue that 
not only affects the individuals themselves, as the illness may also have consequences for their 
families, those close to them, and society as a whole. In addition, there is no cure for dementia, 
but an optimal offer of care and services may alleviate its impact on the individuals themselves, 
those close to them or society.   
Given these findings, the Superior Health Council (SHC) decided to offer recommendations with 
the intent of providing proper information on this illness to the public, patients and their families, 
the professionals concerned as well as the authorities. In order to do so, the Council examined 
the various existing “dementia plans" and reports available on this issue in Belgium as well as the 
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various guidelines provided in the international literature. In addition, the SHC devoted particular 
attention to the  2013 ALCOVE report (Alzheimer Cooperative Valuation in Europe – European 
Joint Action on Dementia - 2013),  which offers a series of recommendations on epidemiological 
issues, diagnosis, behaviour disorders, advance directives and exposure to neuroleptics.  Among 
other things, the aim was to assess how these recommendations could be implemented in 
Belgium. The Council also cooperated with the Belgian Psychotropics Expert Platform (BelPEP) 
in order to draw up recommendations regarding the use of psychopharmaceuticals in elderly 
people.   
Taking into account all of these documents as well as the research conducted on this issue, the 
working group ultimately decided that the SHC advisory report should focus on the quality of the 
diagnosis on the one hand, and on the appropriateness of taking an analytical approach to 
managing the altered behaviour that may be linked to dementia on the other. Indeed, these 
alterations often worsen the distress of the patients and those close to them, whilst the only 
treatment provided for them often merely consists of a pharmacological approach, the full limits 
of which have, however, been revealed in a previous advisory report of the SHC (SHC 8571, 
2011). Finally, the SHC also considered it important to look at several ethical (and legal) questions 
raised by this issue.  
 
I METHODOLOGY 
After analysing the request, the Board and, when appropriate, the Chair of the area mental health 
identified the necessary fields of expertise. An ad hoc working group was then set up which 
included experts in psychiatry, neurology, psychology, ethics, geriatrician, general practice. The 
experts of this working group provided a general and an ad hoc declaration of interests and the 
Committee on Deontology assessed the potential risk of conflicts of interest. 
 
This advisory report is based on a review of the scientific literature published in both scientific 
journals and reports from national and international organisations competent in this field (peer-
reviewed), as well as on the opinion of the experts. 
 
Once the advisory report was endorsed by the working group, it was ultimately validated by the 
Board. 
 
II ELABORATION AND ARGUMENTATION 
1 Dementia: illness and care diagnostics and recommendations for practice  
1.1 Introduction 
Older individuals often find themselves facing cognitive problems. As the latter can range  from 
age-related cognitive changes through mild cognitive problems to a full-blown dementia 
syndrome, it is important to recognize the deficits. This allows professional caregivers to intervene 
when necessary and to provide support for the patients and their caregivers.  
The normal ageing brain is characterized by a loss of brain weight and volume, which  is a process 
that starts in the frontal lobes. The frontal lobe plays a crucial role in executive functions, attention 
and concentration, multitasking, speed processing, … and it is these functions that are usually 
compromised in the elderly. This may lead to certain difficulties in activities of daily living (ADL), 
but their neurocognitive functions remain “normal” as long as they are still able to live 
independently. Typical problems arising among healthy older individuals are difficulties 
concentrating in a distracting environment as well as difficulties multitasking, difficulties   
remembering the names of people, things or facts  and a slowing reaction speed.   
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Being aware of the factors that  can adversely affect cognition and concentration (such as e.g.   
fatigue and/or depressive feelings) and addressing them are the most important tools for living 
with age-related cognitive problems. 
With the growing knowledge on cognitive functioning, it became quickly apparent that there was 
a wide discrepancy between  normal cognitive ageing and a dementia syndrome. According to 
Petersen’s criteria,  Mild Cognitive Impairment (MCI) refers to a degree of cognitive impairment 
that  is not normal for healthy individuals of the same age, but does not induce dependency in 
daily functional abilities, which can be normal or slightly abnormal. Mild cognitive loss refers to 
the first stage of cognitive impairment, when  patients or their relatives become aware of the signs 
and symptoms of cognitive decline. MCI is a well-described risk factor for dementia and thus often 
referred to as a predementia phase of impaired cognition and functioning, even if the evolution of 
the syndrome is quite variable.  
MCI comprises a heterogeneous group of neurocognitive disorders, characterised by memory 
loss, and/or impaired executive functions, language or visual-spatial skills, which are severe 
enough to be noticed by others, but  not severe enough to significantly interfere with daily living. 
An impairment in episodic memory (i.e., the ability to learn and to memorize new information 
consciously) is more commonly observed when  Alzheimer’s disease (AD) is the underlying cause 
of the MCI, which  may, in these cases, progress to AD dementia.  
Between 6 and 25 % of MCI patients will evolve into Alzheimer’s dementia or other dementia 
syndromes each year (McKhann et al., 2011; AAN, 2001). 
 
Dementia is a common syndrome in the elderly. It occurs in 10% of people over 65, and 1 in  2 
over-85-year-olds  will suffer from a dementia syndrome. As the life-expectancy of the developed 
world in particular goes up, the prevalence   of dementia is liable to  take on epidemic forms.  
However, other very recent data also show that there is a decrease in incidence in the West 
(Matthews et al, 2013), which is probably due to the fact that about 50% of AD cases are linked 
to  lifestyle choices (Barnes & Yaffé, 2011) . 
For these reasons, the early detection and diagnosis of cognitive decline or dementia are highly 
situated on the political healthcare agenda. In recent years, the development of diagnostic tests 
that allow diagnosing AD in the prodromal and even in its preclinical phase (biomarkers, 
presymptomatic genetic testing) have taken a leap forward.  
The diagnostic process may in fact be divided into four key stages, viz.  detection, diagnosis, care 
diagnosis and monitoring (Buntinx et al, 2011; The European Joint Action on Dementia, 2013). 
 
1.2 Screening and detection 
1) Screening 
 
Screening is a process that aims at identifying people who appear to be healthy but who may be 
at an increased risk of developing a particular disease or condition. They can then be offered 
information, further tests and appropriate treatment to reduce their risk and/or any complications 
arising from the disease or condition. For screening programs and strategies to be carried out,   
they need to meet the Jungner and Wilson criteria (Wilson & Jungner, 1968). 
According to the literature, systematic screening for neurodegenerative brain disorders is not 
advisable, given the following facts :   
 
- The Wilson and Jungner criteria are not sufficiently met to justify screening (Wilson & 
Jungner, 1968). 
- Tests to detect pre-clinical stage/asymptomatic AD and other forms of dementia 
(screening) do not display sufficient efficacy (except for genetic testing in familial cases).  
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- There are no reliable tests available (except for genetic testing in familial cases) to screen 
for early signs of cognitive decline that make it possible to predict a future diagnosis until 
people actually complain of  memory loss (as per symptom definition). 
- Dementia and cognitive impairment due to neurodegenerative brain disorders are still 
untreatable conditions, as there is no physical cure available, nor any means to stop its 
progress .  
- It is not yet possible to reverse or stabilise the loss of memory through pharmacological 
intervention.   
- There are currently no scientific data available that show whether or not identifying 
cognitive decline in non-at-risk elderly people is cost-effective, even though some 
publications do show a decrease in institutionalisations in the event of early identification 
(Barnett et al., 2014; Getsios et al., 2012). 
- Several publications have shown that it is not always appropriate to make an early 
diagnosis (De Lepeleire et al., 2004; De Lepeleire, 2009; Vernooij-Dassen et al., 2005; De 
Lepeleire & Heyrman, 1999). The risks include: negative attitudes towards dementia, 
misdiagnosis, and loss of autonomy. Screening is liable to cause harm to the patients and 
their relatives that could be of a personal, economic, psychosocial and legal nature. 
 
In order to facilitate a process of adjustment and adaptation, it is proposed that early diagnosis 
should be replaced by timely diagnosis, a diagnosis made at  the right moment, at the earliest 
stage as acceptable for patients and relative(s), and in response to an unmet need of a patient or 
relative occurring at a point when the person in question and their family are ready to undergo 
assessment. “Timely” implies a more person-centred approach that benefits the patient, one that  
does not tie the diagnosis to any particular stage of the disease  but rather to the need 1/ for 
accurate information on new developments  in  the field of dementia, especially as regards  novel 
biomarkers and treatments (cure & care + clinical studies) and 2/ for enhancing the  empowerment 
of all patients and, in fact, for promoting advanced care planning, which is organised in 
cooperation with these patients (especially if there is NO screening). 
 
2) Detection – Timely diagnosis 
 
Early detection refers to recognizing possible warning signs of a disease and taking prompt 
action that leads to early diagnosis (WHO). This strategy is often applied in primary care and 
described as case finding. The aim is e.g. to identify specific target groups with specific risks 
(familial risk,  patients with Down syndrome and other learning disabilities, stroke patients, 
patients with Parkinson's disease or with suspicious signs and symptoms (e.g. cognitive 
complaints)).  
Targeted screening essentially begins with direct observation and communication.  
 
It is also important to recognise the presence of an MCI syndrome, thus making it possible to 
give the patients and their caregivers all necessary information and evidence-based treatments.  
The cognitive impairment should always be examined in order to determine its aetiology. In many 
cases no therapeutic action will be undertaken, but follow-up remains mandatory in order to 
predict future problems (e.g. MCI in Lewy-body related syndromes, in frontotemporal lobar 
degeneration (FTLD), in vascular pathologies). Many disorders apart from AD are liable to induce 
MCI. It follows that the prognosis for MCI will differ depending on the aetiological diagnosis and 
that treatment is available for certain causes (such as depression, hypothyroidism, sleep 
disorders, side effects of medication etc.).    
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The NICE guideline [NICE, 2006] suggest that the assessment in patients with a cognitive 
problem includes 
- a thorough anamnesis of the patients and their  caregivers. An additional tool in this 
assessment can be the IQCODE (Informant Questionnaire for Cognitive Decline in the 
Elderly). (Harrison et al., 2014). However, there are  not enough  data available to date to 
suggest that the IQCODE should be part of the work-up of  cognitive disorders (Cochrane, 
2015); 
- profiling of cognitive functioning and mental health. As depression can induce cognitive 
dysfunction that may be severe enough to be mistaken for a dementia syndrome, 
screening for depression should also be performed; 
- a general physical and clinical neurological examination ; 
- checking the medication in order to identify and minimize the use of drugs. Attention 
should also be paid to over-the-counter products that may have a (side) effect on cognitive 
functioning.  
 
Next to the anamnesis and physical examination, the NICE guidelines suggest that  further work-
up should include a  blood test (complete blood cell count, glucose, electrolytes, liver, kidney and 
thyroid functioning, VitB12 and folate levels).  
 
As regards MCIs that are induced by a neurodegenerative disorder, the debate on the 
benefits, desirability and necessity of disclosing the diagnosis is still ongoing.  
If the diagnosis is one of an incurable neurodegenerative disorder, patients may decide how far 
they wish to go in the diagnostic procedure. We emphasize that this thorough work-up is not 
mandatory nor obligatory for  every patient with a cognitive disorder, as the patient has the right 
not to  know, given the incurable nature of neurodegenerative brain disorders. The decision to 
initiate a diagnostic procedure or not, regardless of whether the latter is conducted by the  general 
practitioner (GP) or hospital specialists, should always be taken with the patients and their 
caregivers. Whether or not a diagnostic process should be initiated depends on factors that are 
inherent to the patient as well as on relative characteristics. An analysis of the risks and benefits 
of examining the signs and symptoms should therefore be conducted before embarking on this 
course of action. Patients who are assessed for the possibility of dementia should be asked 
whether  they wish to know the diagnosis and with whom this should be shared.  
More specifically, if they do decide they want to know the diagnosis, the patients and their 
caregivers should be well aware of what the consequences are of knowing the diagnosis, of what 
can be and can’t be done in terms of treatment, , and of how the disease will evolve, … This 
information will be offered progressively and in a manner that is tailored to the patients’ and 
caregivers’ growing ability to take it all in (advance care planning). 
 
From a patient and caregiver perspective, there are several reasons why a further diagnostic 
approach has an additional value: 
- Acknowledging the problem can induce a sense of relief in patients and caregivers. « Our 
complaint is taken seriously ». 
- Knowing that cognitive problems that are induced by certain conditions (e.g. sleep 
disorders, depression, side effects of medication, …)  will not progress into  dementia will 
be of great  relief to patients and caregivers and will allow for appropriate action to be 
taken. 
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- Having a diagnosis allows the patients and their (professional) caregivers to get a better 
understanding of  the problem, and makes it possible to manage the   patients and  their  
cognitive problems more appropriately. Also, counselling can only start once  a correct 
diagnosis is available.  
- It offers the opportunity of addressing the right to know, increasing  the quality of life, 
providing early access to intervention or treatment. Dementia and cognitive impairment 
due to neurodegenerative brain disorders can be treated symptomatically (psycho-
education, cognitive rehabilitation, symptomatic pharmacological treatment options). 
There are currently only few clinical trials on curative or slowing therapeutic strategies that 
might have an effect on cognition in MCI patients (see Dominantly Inherited Alzheimer 
Network; Belleville, 2006; Belleville, Brain 2011; Grande, 2014). It also remains important 
to follow these patients, in order to,  initiate a disease slowing therapy when a beginning 
Alzheimer’s dementia is suspected. 
- It offers the opportunity of allowing the patient to take decisions with regard to the end of 
life and advanced care planning. 
- Some cognitive disorders can be caused by treatable or modifiable conditions, e.g. 
hypovitaminosis, hypothyroidism, or medication-related side effects. 
- The prognosis depends on underlying aetiologies (i.e. vascular dementia has a worse 
prognosis than AD; the prognosis is different in the event of  dementia with Lewy-body 
(DLB)  than in AD). 
- Treatments are disease-dependent. 
The first steps towards further diagnosis are taken as a result of a thorough consideration and 
complex interaction between the patients and their relatives or social networks. In most cases, 
the latter are  the requesting party and plan  the first contact with the healthcare professional (i.e. 
the GP or hospital specialist). 
Before consulting a medical doctor, the patient and the relative should ask themselves the 
following questions: 
- do I want a diagnosis or do I want not to have it ? 
- why do I want a diagnosis or want to ignore it ? 
- what will I want to know and will I ask first ? 
When patients and relatives suspect a  cognitive decline, they are entitled to  the following: 
- efficient measures and instruments adapted to them ; 
- competent and skilled professionals ; 
- accessible professional care ; 
- awareness of the problem by the community and healthcare organizations ; 
- information ; 
- adapted care and treatment. 
Most persons with symptoms of cognitive decline first turn to their family doctor.  
This professional is expected to 
- detect and find cases,  
- initiate the diagnostic and differential diagnostic process,  
- meet and draw up a list of care needs,  
- provide care, 
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- refer,  
- follow up on the patient, 
- be aware of the patient context, 
- initiate advance care planning and contribute to it. 
Most GPs feel reluctant to talk about cognitive decline and they enumerate many barriers to 
further exploring  the issue. These barriers can be lowered when the following conditions are met 
(Schoenmakers & De Lepeleire, 2011; De Lepeleire, Gorissen, Vermandere, & Schoenmakers, 
2009):  
- GPs possess knowledge: through educational interventions.  
- GPs have direct access to specialized care: direct and low threshold contact with 
specialists and short waiting-lists. 
- GPs are supported by a case manager. 
GPs receive the support of  and have access to guidelines: access to acceptable guidelines and 
to decision support mechanisms (It could also be useful to set up a computerised system using 
“pop-up" windows to provide doctors with a clear picture of what needs to be done and when in 
real time during the consultation.  
- GPs are skilled and trained as reference doctors. 
Patients and relatives turn to other professional caregivers with a particular unmet care need. In 
a growing number of cases and depending  on the local care provision, these services can also  
initiate a diagnostic assessment, provided they work in close coordination with the GP and the 
memory clinic team. 
Most of these professional caregivers are neuropsychologists, nurses, social workers and 
occupational therapists who are well-versed in  the particular features of dementia and the 
concomitant care needs. These caregivers should 
- possess knowledge through educational interventions,  
- be aware of the problems and unmet needs, 
- be in direct contact with the treating physician (in most cases,  the GP, but also members 
of memory clinics), 
- be able to  draw up inventories of the care needs (assessment), organise care and set up 
a multidisciplinary consultation (intervention). They should use a  personalised care 
approach  to do so,  
- guarantee follow-up, 
- see the patients at home. 
Professional caregivers assess and intervene in an objective way that is tailored to the patient’s 
needs. Their approach is guided and supported by 
- direct and indirect observation, 
- adequate instruments: OLD-questionnaire, Niet-pluis index, FRAIL, scales adapted for 
instrumental activities of daily living (IADL), grids for daily activities, MiniCog. 
Some patients turn to a specialist straight away, viz. in descending order of frequency : a 
neurologist, a geriatrician or a psychiatrist.  
 
When initiating the diagnostic process, the following issues should be addressed or discussed:  
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- Pre-assessment counselling should be given (‘informed consent’): level of knowledge, 
coping, needs, … 
- Psycho-social support should be available and offered. 
- There should be enough insight into the pre-existing relationship between people with 
symptoms and their relatives.  
- There should be enough time available, as well as appropriate and sufficiently equipped 
facilities. 
- The follow-up should be explicitly planned.  
Upon ethical consideration and following the informed consent of the patient and/or caregiver a 
further diagnosis may be considered. The following issues should be addressed prior to proposing  
further diagnostic investigation as well as in order to  plan the follow-up:  
- Evidence of a change in cognition compared with previous functioning;  
- Performance in one or more cognitive domains  is worse  than would be expected based 
on  the patient’s age and educational background, including memory, executive function, 
attention, language, visual-spatial skills or behaviour; 
- Extent to which the patient’s independence in functional abilities is preserved, although 
these abilities may be altered, and the person may be less efficient at performing normal 
ADL;  
- Insufficient impairment for a diagnosis of dementia. 
Patients and relatives should prepare their visit to the medical doctor. For this purpose they can 
use a checklist as proposed by the World Alzheimer-organization ‘Know the 10 signs’, “IQCODE”, 
(Jorm, 1994; Law & Wolfson, 1995). Thus, such tools aimed at providing assistance in putting 
problems into words should be made available to patients and their families in the waiting rooms 
of non-specialist physicians (GP and others), in conjunction with a large-scale information 
campaign aimed at the general population.  
Second, it is preferable that patients be accompanied by a close relative during at least one such 
contact to contribute to the  anamnesis and to help draw up an inventory of the unmet needs of 
both parties.  
 
As a later step, objective measures and instruments can be applied to confirm the suspected 
cognitive decline, although there is little evidence in support of the efficacy of instruments for 
targeted screening. Indeed, the latter lack specificity and display a variable sensitivity. These 
instruments include:  
The Mini Mental State Examination (MMSE) ; 5 words; Clock drawing test; BREF, MOCA, ACE 
and ACE-R, MiniCog (http://www.azalma.be/download/geriatrie/Mini-COG.pdf).  
Less frequently used possibilities include 6-item Cognitive Impairment Test (6-CIT), General 
Practitioner Assessment of Cognition (GPCOG), 7-minute screen. 
In patients in whom cognitive decline is suspected, cognitive testing should include examining  
attention and concentration, short and long term memory, orientation, language and executive 
function and praxis. Neither the GP nor even the specialist should make the diagnosis on their 
own, as this  requires a team, made of at least a specialist and a skilled neuropsychologist.  
Indeed, only a thorough neurological examination can uncover any dysfunction, especially given 
the fact that there are amnestic MCIs and other dysexecutive syndromes.  
The circumstances of each individual patient (i.e. age, level of education, skills, prior level of 
functioning, psychiatric illnesses, sensory or other physical impairments) should be taken into 
account when interpreting the results of these tests.   
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Of course, the accuracy of the diagnosis is determined by the clinical follow-up, and the detection 
of the underlying pathology is dependent on further examinations such as neuropsychological 
profiling, biomarker analyses such as brain imaging, cerebrospinal fluid (CSF) biomarker analysis 
or even DNA analysis.  
Moreover, even if no cognitive complaints were objectified during the neuropsychological 
examination, regular follow-up should then be offered and this assessment should be carried out 
again because the risk goes up once there has been a complaint (Steward, 2012). Normal test 
results do not mean that there is no need to conduct a more thorough examination, nor do low 
scores mean that this is a case of dementia, and especially of neurodegenerative disease. 
Therefore, in case of a (hetero-)anamnesis suggestive of cognitive decline, patients with a normal 
screening test too can be referred to a memory clinic if a diagnostic work-up is desirable.  
 
In case an aetiological diagnosis of the dementia syndrome is desired, this will require additional 
diagnostic tests in order to obtain (biomarker) evidence for the causative brain disorder. 
Structural brain imaging can also be used to exclude other  treatable causes. 
A biomarker-based diagnosis of AD can be used in clinical practice to diagnose AD in the early 
stage of dementia; viz. 
- in case of minimal or mild cognitive impairment, provided that the patient wants to know 
the result; 
-  in atypical forms with prominent non-memory impairment;  
- to identify AD in patients with mixed pathologies and  
- in case of an ambiguous (AD versus non-AD) dementia diagnosis (Engelborghs, 2013; 
Molinuevo et al., 2014).  
Biomarkers that can be used are MR brain imaging to assess medial temporal lobe / hippocampal 
atrophy, FDG-PET scan of the brain and a lumbar puncture for CSF biomarker analyses. 
 
At the time of the diagnosis of dementia, as well as  at regular intervals afterwards, assessments 
should be made for comorbidities and psychiatric features associated with dementia (Behavioural 
and Psychological Signs and Symptoms of Dementia – BPSD), to ensure the optimal 
management of these conditions. 
 
1.3 Diagnosis 
1.3.1 Subjective cognitive impairment 
People with a subjective complaint of decline in their cognitive abilities, but in whom no impairment 
could be identified even after a comprehensive assessment, display a slightly elevated risk of 
developing an MCI and possibly dementia.   
Unlike MCI, there are no clear diagnostic criteria for SCI. The fact that it is a risk factor means 
that such complaints should not be neglected and that a follow-up should be offered.  
 
1.3.2 Mild cognitive impairment 
Diagnosing an MCI involves verifying whether the patient meets Petersen's (2004) criteria: 
complaints of cognitive disorders that are confirmed by their relatives, objective confirmation of a 
cognitive impairment taking into account the person’s age, overall cognitive preservation, and 
whether or not the functional activities of daily living are normal or slightly abnormal. The cognitive 
impairment can concern either isolated memory or any other function, isolated or in association. 
The assessment should be performed by means of a full neurological assessment (Bedeco, 
2015). 
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Depending on the cognitive profile, an aetiological search aimed at finding markers of the 
underlying disease may be conducted with the patient's consent.   
 
1.3.3 Alzheimer’s disease 
AD has traditionally been defined as a type of dementia. The clinical diagnostic criteria such as 
those from the National Institute of Neurological and Communicative Disorders and Stroke – 
Alzheimer’s Disease and Related Disorders (NINCDS-ADRDA) were based on ruling out other 
conditions and disorders that could lead to the same clinical symptoms. Two major limitations of 
these criteria were that: i) the clinical diagnosis of AD could only be considered as ‘probable’ 
during the patient’s lifetime and could only be definitive if a  post-mortem was done to confirm it ; 
ii) the clinical diagnosis of AD could only be made when the disease had progressed to the point 
of causing significant functional disability, and met the threshold criteria of dementia. The fact that 
there were no clinical criteria available at the time for the other types of dementia  and the lack of 
biomarkers resulted in a low specificity in differentiating AD from other dementias. 
In 2007, the International Working Group (IWG) (Dubois et al., 2007) for new  research criteria for 
the diagnosis of  AD provided a new conceptual framework that no longer looked upon  AD as a   
clinico-pathological entity, but rather as a clinico-biological entity. These 2007 IWG criteria 
suggested that AD could be recognized in vivo and independently of dementia if two mandatory 
features were present. The first was a core clinical phenotypic criterion, requiring evidence of an 
amnestic syndrome of the hippocampal type. The second criterion was the presence of biomarker 
evidence consistent with AD in structural Magnetic Resonance Imaging (MRI), molecular 
neuroimaging with Positron Emission Tomography (PET) or CSF analysis of amyloid β and tau 
protein (total and phosphorylated) levels. These criteria were updated in  2010 and 2014 (Dubois 
et al., 2010; Dubois et al., 2014). The diagnosis of AD can be simplified by requiring the presence 
of an appropriate clinical AD phenotype (typical or atypical) and a pathophysiological biomarker 
consistent with the presence of Alzheimer pathology. 
 
1.3.4 Vascular dementia 
Next to AD, vascular dementia accounts for approximately 17% of all dementia disorders 
[http://www.alzheimers.org.uk]. Another 10% of patients with dementia suffer from mixed 
dementia, i.e. the combination of Alzheimer’s pathology and vascular changes in the brain.  The 
NINDS-AIREN Workshop for Vascular Dementia proposed clinical criteria to facilitate a 
standardized definition of Vascular dementia (Erkinjuntti, 1994) :  
 Dementia defined by cognitive decline from a previously higher level of functioning and 
manifested by impairment of memory and of at least one other cognitive domain. Deficits 
should be severe enough to interfere with ADL not due to the physical effects of stroke 
alone. 
 Cerebrovascular disease (CVD) defined by the presence of focal signs on neurologic 
examination consistent with stroke (with or without history of stroke) AND evidence of 
relevant CVD by brain imaging (CT or MRI). 
 A relationship between the above two disorders manifested or inferred by the presence of 
one or more of the following:  
(a) onset of dementia within 3 months following a recognized stroke;  
(b) abrupt deterioration in cognitive functions; or  
(c) fluctuating, stepwise progression of cognitive deficits. 
 Clinical features consistent with the diagnosis of probable vascular dementia include: 
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(a) early presence of gait disturbance; 
(b) history of unsteadiness and frequent, unprovoked falls; 
(c) early urinary frequency, urgency, and other urinary symptoms not explained by 
urologic disease; 
(d) pseudobulbar palsy; 
(e) personality and mood changes, abulia, depression, emotional incontinence, or 
other subcortical deficits including psychomotor retardation and abnormal 
executive functions. 
 
1.3.5 Frontotemporal Dementia (Sieben et al, 2014) 
FTLD is an anatomopathological descriptive term referring to a disorder characterized by the 
relatively selective atrophy of the frontal and anterior temporal lobes of the brain. Apart from this 
commonality, FTLD is a clinically, genetically and pathologically heterogeneous group of 
disorders. Because disease onset often occurs before the age of 65  in 75–80 % of the patients, 
FTLD is considered a presenile dementia. In the age group  45 to  65, the prevalence of FTLD 
has been estimated between 10 and 30 per 100,000.  In the elderly, FTLD is less common, 
accounting for approximately 5 to 10% of dementia syndromes. 
FTLD can manifest as two clinically recognized subtypes based on the presenting and 
predominant features of either behavioural and personality changes, or language disturbances. 
The behavioural variant of frontotemporal dementia (bvFTD) is characterized by severe changes 
in behaviour and personality such as disinhibition, apathy, loss of empathy, or stereotypic 
behaviour, leading to a loss of social competence. Executive functions are impaired, while at least 
in the initial stages of the disease, memory and perceptual-spatial skills are well preserved. As 
the differential diagnosis in patients with psychiatric disturbances or AD is not always 
straightforward, the ‘International Behavioural Variant FTD Criteria Consortium’ developed 
international consensus criteria for bvFTD. According to these criteria, sub-classifications were 
made in possible bvFTD defined by clinical criteria, probable bvFTD supported by neuro-imaging 
data, and definite bvFTD confirmation by neuropathological evidence or a pathogenic mutation 
(Rascovsky et al., 2011). bvFTD accounts for more than 50 % of the FTLD patients. The onset of 
bvFTD is typically before the age of 65 years, with an average onset age of 58 years. 
If the patient presents with language difficulties, a diagnosis of primary progressive aphasia (PPA) 
is made. PPA was originally further categorized into progressive non-fluent aphasia (PNFA) and 
semantic dementia (SD) (Josephs  et al., 2011). However, the clinical picture of a number of PPA 
patients did not fit either diagnosis, which led to the description of the third variant, logopenic 
progressive aphasia (LPA). The lack of clear definitions of the three subtypes led in 2011 to new 
recommendations for the sub-classification of PPA into non-fluent/agrammatic variant PPA (the 
former PNFA), semantic variant PPA (the former SD) and the logopenic variant PPA (also known 
as LPA) (Gorno-Tempini et al., 2011). Non-fluent/agrammatic variant PPA or PNFA is 
characterized by effortful speech and grammatical error-making, with relatively preserved 
language comprehension. PNFA is the second most prevalent presentation of FTLD, accounting 
for a large 25 %. Semantic variant PPA or SD presents with impaired comprehension and 
conceptual knowledge with concomitant development of anomia, while speech production is 
spared . SD presents in 20–25 % of the FTLD patients. LPA is mostly associated with a 
neuropathological diagnosis of AD  and is not considered part of the FTLD group of disorders. 
Based on the evidence supporting the diagnosis of PPA, the label “possible” (clinical features), 
“probable” (clinical findings in combination with neuro-imaging) and “definite” (after post-mortem 
examination or when a gene mutation is known) are provided. 
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1.3.6 DLB and Parkinson Dementia (McKeith et al, 2005) 
Another 10% of patients with dementia suffer from a Parkinson-related dementia. It is important 
to look upon Lewy-body dementia and Parkinson dementia as both ends of the Lewy-body 
disease spectrum. In Lewy-body dementia, the cognitive syndrome manifests itself before the 
motor difficulties, or within a year after the onset of motor symptoms, whereas Parkinson dementia 
occurs in 78% of patients with Parkinson’s disease (McKeith & Mosimann, 2004). 
Consensus guidelines for the clinical and pathologic diagnosis of DLB were published in a 
report of the consortium on DLB international workshop (McKeith et al., 2005)  : 
 
1.4 Care diagnostics 
The ideal way to meet the care needs is to provide the best possible compromise between the 
wishes of the patient and what is deemed necessary by professional healthcare providers. The 
complaints associated with dementia process often make it impossible for the individuals 
  
Superior Health Council 
www.shc-belgium.be 
 
− 15 − 
themselves to define their own care needs.  In order to do so, an appeal will have to be made to 
those close to the patient (informal and formal care). 
The care diagnosis is also inextricably linked to the diagnosis of the illness (De Malsche & De 
Lepeleire, 2011; Vermandere, 2009; Vermandere et al., 2012). The former must be an integral 
part of the diagnostic process. It is concerned with making an inventory of care needs, which is 
of paramount importance. Thus, a care diagnosis allows for better and timely care planning as 
well as a greater quality of life for the patient and the informal carer. With the GP often possessing 
valuable information on the patients and their informal carers, there should be enough emphasis 
on communication between the GP and the specialist and vice versa. In addition, it is the GP who 
will follow up on the patients after their visit to the specialist.  
The care diagnosis includes both aspects that pertain to the patient as well as aspects that relate 
to the informal care. As regards the patient, attention needs to be paid to the following items, 
which need to be checked on a regular basis :  
- Information on disclosing the diagnosis and its impact on the patient; 
- Information on the patient's mood and how they experience their quality of life as well as 
how it can be improved; 
- Assessment of ADL and IADL functioning; 
- Identity and individuality of the patient:  profession, ideology, purpose, values and norms; 
spirituality;  
- Falling hazard and adjustments to the home to avoid falls; 
- Discuss the ability to drive and possibly refer to CARA;  
- Advance care planning, provided the diagnosis was disclosed: wishes for the future, views 
on institutionalisation, legal aspects of patient representation and guardianship, 
declaration of intent regarding the care to be provided in case of legal incapacity.   It is of 
crucial importance to initiate a dialogue on these issues.  
As regards the informal carer, heed needs to be paid the following items:  
- Information on balancing between burden and capacity (mental and social well-being) and 
personal experience of the  burden of care  with possible referral to single or group  
psycho-education; 
- Assessment of physical health;  
- Role in overseeing the intake of any medication; 
- Need for personal supervision by the informal carer: partial or continuous. 
As regards advance care planning, it is of paramount importance to initiate the dialogue on this 
issue.  The GP is a key point of contact in this regard.    
 
1.5 Monitoring the illness- and care process 
More time will be required for supervision as the illness progresses. In moderate to severe 
dementia, informal carers often take it upon themselves to provide full-time support (in terms of 
ADL, incontinence, help with taking a bath, and help with taking meals and with mobility). Most 
informal carers experience a heavy burden of care. They report that the responsibility they have 
taken upon themselves has resulted in twice more physical stress as well as a high level of 
emotional stress (Waldemar et al., 2007; Schoenmakers & Maturitas, 2010). Vacations, leisure 
time and personal activities fade into the background. The timely involvement of home care and 
respite care services can be helpful.   
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Psychosocial interventions need to be available in a flexible manner (i.e. based on and tailored to 
the patient's needs, upon request) to the families of people with dementia (Brodaty et al., 2003). 
The autonomy of the informal carer should always be a key priority. Yet providing efficient training 
to informal carers or offering them psychosocial support is an intervention that covers a wide 
range of activities. Their aim, however, is always the same: to strengthen the informal carer's 
load-bearing capacity (offer strategies to manage stress, to be able to cope with behavioural 
problems, to reduce the workload, to get more satisfaction from providing informal care).  
Interventions with multiple components are usually effective, whilst studies involving a single 
component yield contradictory results. Such components include advisory sessions, taking part 
in support groups, telephone counselling, assessment of the patient's individual situation, referral 
to a psychiatrist, and joining a network of families (KCE, 2011). 
Furthermore, every person with dementia or those close to them should have access to a personal 
care attendant with expert knowledge on dementia   during the dementia process.  
   
It is advisable to use the BelRAI tool for the further monitoring of the care process.  Furthermore, 
the guidance for care diagnosis is also useful during a multidisciplinary consultation that aims at 
drawing up an inventory of the care needs of a person with dementia living at home. This 
document is divided into 4 chapters: the patient, the informal carer, the safety of the patient and 
decisions concerning the end of life (Vermandere et al., 2012). 
 
Performing illness and care diagnostics, interpreting the data, providing treatment for symptoms 
such as BPSD, meeting the needs of the patients and alleviating the stress faced by their informal 
carers require specific professional skills and, ideally, a multidisciplinary approach at various 
levels.   
 
1.6 Recommendations 
It is not easy to make an aetiological diagnosis of dementia (aside from certain genetic forms and 
possibly some biomarkers). This would require binding quality criteria that would need to be 
complied with for e.g. the reimbursement of diagnostic procedures and any subsequent treatment.   
The reimbursement of neuropsychological testing depends on the impairments that characterise 
neurocognitive deterioration. The reliability of the diagnostic procedure is a current requirement 
for admitting patients into cognitive rehabilitation, without it being specified what such a procedure 
should involve. Reimbursement for AChE-inhibitor medication is subject to a diagnostic procedure 
that goes back to the 1980s: an update is required. Note that these quality criteria should apply 
to all types of dementia, not just AD. 
There are currently no guidelines available in Belgium on the diagnosis of dementia. The NIHDI 
and the CEBAM have adapted international guidelines to fit the situation in Belgium. They have 
done this for various diseases, including dementia (Project Duodecim Guidelines), but these 
guidelines have yet to be implemented and their use needs to be promoted.  
The procedure which allows GPs to correctly convey all the necessary information to medical 
specialists should also be promoted to physicians as a means to boost its use.  
The funding provided for the diagnosis should also enhance the quality of the procedure, 
especially as regards its multidisciplinary nature. Currently there is no funding for consultations 
between GPs and specialists. One possibility would be to use and adapt the example of the 
"COM" (multidisciplinary oncology consultation) funding, which has been set up for cases of 
cancer, in order to promote such consultations. The KCE's assessment of this project (KCE 
Reports 239B) has revealed that in 2011, the cases of over 80% of patients were presented at a 
COM and that this improved the quality of care. The use of modern means of communication for 
these COMs should be encouraged with a view to dealing with organisational issues and 
promoting the involvement of GPs. 
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As the quality criteria for clinical work-ups and reimbursement for the diagnosis are enhanced, 
each patient could be authorised to receive more than one opinion, as this often turns out to be 
useful (Cruys et al., 2012). 
 
Thus, the following quality criteria should apply:   
 
- The patients and their caregivers have been given access to a preliminary consultation 
where they could  express their needs and expectations and the potential risks and 
benefits of a diagnostic work-up have been reviewed and the patients have consented to 
this procedure. 
- The diagnostic procedure included 
 a mental status examination ; 
 a thorough neuropsychological examination including precisely defined tests ;  
 structural brain imaging using appropriate (defined) incidences and sequences ;  
 other biomarkers if structural imaging was insufficient to provide the diagnosis. 
- The patients and their caregivers have been informed of the results of these procedures 
and of their implications in term of prognosis and have been offered different therapeutic 
interventions and kinds of support (psychological, social). 
- The patients’ GPs have received a detailed report of each of the diagnostic steps. 
 
2 BPSD and psychopharmacology 
2.1 Introduction 
Changes in behaviour are highly prevalent in patients suffering from cognitive impairment, as 
early as in the MCI stage. Addressing them  is not tantamount  to choosing the proper medication. 
 
The history of the Behavioural and Psychological Symptoms in Dementia (BPSD) concept is 
recalled in the IPA BPSD Specialists Guidelines released by the International Psychogeriatric 
Association  
“In 1996, the International Psychogeriatric Association (IPA) convened the Consensus 
Conference on the Behavioural Disturbances of Dementia. The 1999 Update Consensus group, 
produced a statement on the definition of the BPSD: “The term behavioural disturbances should 
be replaced by the term behavioural and psychological symptoms of dementia (BPSD), defined 
as: symptoms of disturbed perception, thought content, mood, or behaviour that frequently occur 
in patients with dementia.” (Finkel & Burns, 1999) 
The European Alzheimer’s Disease Consortium also noted that the term BPSD is not a unitary 
concept and recommended that it should be divided into several or more groups of symptoms 
(e.g., apathy, mood/agitation, psychosis), each possibly reflecting a different prevalence, course 
over time, biological correlate, and psychosocial determinants (Robert et al, 2005).” 
 
Different groups, subgroups and clusters have been proposed over time. The aim  here is not to 
discuss which of them is the most valuable but to use this approach to provide a practical guide 
on how to manage patients who have dementia and who experience behavioural and/ or 
psychological changes. 
 
In its 2011 advisory report on “The impact of psychopharmaceuticals on health, with a particular 
focus on the elderly" (SHC 8571, 2011), the SHC had already pointed out several items of concern 
regarding the use medication in elderly patients, especially elderly people with dementia. Thus, 
the following observations were made in this advisory report: 
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"- The adverse effects of benzodiazepines are more frequent and more severe in the elderly and 
may worsen any existing dementia or interfere with its diagnosis. 
 - A rise in mortality has recently been observed for all antipsychotic medication in elderly people 
with dementia, in all likelihood as a result of strokes (Schneider & al., 2006).  
- Antipsychotic medication can be discontinued without too much difficulty.  Most studies have 
been conducted with patients with Alzheimer-type dementia or other forms of dementia who were 
receiving antipsychotic medication as a means to treat behavioural problems. In these studies, 
antipsychotic medication was discontinued abruptly in patients with Alzheimer's disease, without 
gradual tapering. (Ballard & al., 2008 ; Ballard & al. 2009 ; Cohen-Mansfield & al., 1999 ; Ballard 
& al., 2004 ; Bridges-Parlet & al., 1997 ; van Reekum & al., 2002 ; Ruths & al., 2004 ; Ruths & al., 
2008). 
- The high prescription rate is  not consistent with the latest scientific evidence and guidelines 
regarding the indications for initiating psychotropic medication, the effectiveness of alternatives 
to medication,  and the limited time during which these drugs should be prescribed as a rule (in 
case of insomnia, anxiety, stress, acute depression and aggressiveness).  
- These data reveal a public health problem, especially as regards the health of the elderly.  It is 
paradoxical to see that these products are mainly prescribed to elderly people, who are in fact 
more sensitive to side effects that are liable to enhance the symptoms of dementia, thus 
complicating the diagnosis even more.  There is not only a rise in morbidity but also in mortality 
among elderly people with dementia taking antipsychotic medication. "  
 
There is no denying that the issue of using medication has already been well documented. 
However, those working in the field are not always aware that there are alternatives to medication.  
That is why the SHC offers to describe a different type of approach to managing  the behavioural 
symptoms of dementia. Clearly, there is no single strategy (pharmacological or other) that has 
unequivocally been shown to be effective. This report must be looked upon as a set of 
recommendations that are  based  on both the experience of the experts who drew them up as 
well as on existing guidelines (e.g., Voyer, 2009).  
 
2.2 BPSD: Towards a more effective therapeutic approach 
2.2.1 General principles. 
Keep in mind the goal of a given  intervention. 
The first issue is actually the attitude of caregivers (both professionals and non-professionals) 
when faced with  unexpected behaviours: is their main objective to protect themselves or to 
improve their patients’ quality of life, considering that altered behaviour, including agitation, 
reflects some degree of distress (Cummings et al., 2015). 
If the first is true, which is a highly common, if not the most prevalent, kind of response, the aim 
is to  suppress the disturbing behaviour quickly by using neuroleptics or physical restraints, in a 
stereotyped way, regardless of what has caused this type of behaviour. Clinical studies have 
repeatedly demonstrated the poor efficacy and the low benefit / harm ratio of this approach 
(Azermai, 2015, for a review).   
The alternative response, i.e. taking into account the subject’s feelings and attempting to suppress 
the cause of the disturbing behaviour, requires an analytical approach.  Besides having an effect 
on the  administration of medication, it gives the caregiver a sense of control, which can in turn 
have beneficial effects for the patient (Gitlin et al., 2001, Sink et al., 2006). 
 
Step1. 
What term can be used to describe the observed behaviour ? As mentioned above, quite a 
number of classifications have been offered for the disturbing behaviour observed in people with 
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dementia.   The most widely used in daily clinical practice is that of the Neuropsychiatric Inventory 
(NPI, Cummings et al., 1994): 
Delusions 








Aberrant motor behaviour (e.g. pacing, rummaging, repetitive movements) 
Sleep (night insomnia/ day hypersomnia) and Night-time Behaviour Disorders 
(wandering, pacing, inappropriate activities) 
Appetite (hypo / hyperphagia, weight loss or gain) and Eating Disorders 
 
A basic way of grouping together BPSD is to distinguish behavioural signs, i.e. those identified 
through the observation of the patient (Agitation/Aggression, Elation/Euphoria, 
Apathy/Indifference, Disinhibition, Aberrant motor behaviour, Sleep and Night-time Behaviour 
Disorders) from psychological signs, wich are identified after an interview with the patients or their 
families (depression, anxiety, hallucinations, delusions). 
  
Step 2. 
What lies behind the observed behaviour ? 
Factor analysis studies (e.g. Aalten et al., 2007, Petrovic et al, 2007) have made it possible to 
assign individual symptoms/signs to a small  number of factors (e.g. a psychosis factor, the 
components of which are  irritability, agitation, hallucinations and anxiety, a psychomotor factor, 
with  aberrant motor behaviour and delusions, a mood liability factor, with  disinhibition, elation 
and depression, and an instinctual factor, with  appetite disturbance, sleep disturbance, and 
apathy).  Relationships were found to exist between these factors as well as between  the latter 
and non-behavioural variables (Proisti et al., 2011):  “psychosis” can partially explain some of the 
variability of “agitation”, “mood”, and “behavioural dyscontrol”; “moods” can partially account for  
some of the variability of “agitation”, and “behavioural dyscontrol and “agitation” can partially 
explain some of the variability of “behavioural dyscontrol”.   
In the same study, greater cognitive impairment was a significant predictor of the “psychosis”, 
“moods” and “behavioural dyscontrol” factors; younger age/age at onset was a significant 
predictor of the “agitation” and “moods” factors, whereas older age/age at onset was a marginally 
significant predictor of the “psychosis” factor; female gender was a significant predictor of the 
“psychosis” factor, whereas male gender was a significant predictor of the “agitation” factor; long 
disease duration was a marginally significant predictor of the “agitation” factor only. 
Many years earlier, Cohen-Mansfield et al. (1989) had shown links between environmental, 
psychological and general health factors and agitation (Table I), which is in line with the view of 
Lawton (1975), according to which the ability to receive, process and sense  environmental cues 
is compromised in  people with cognitive impairment, making it increasingly difficult for them to 
cope with everyday environmental stimuli. 
In addition, it must be stressed that conditions such as poor eyesight or deafness can induce 
behavioural changes, which range from apathy to paranoid delusion and subsequent agitation.  
Poor eyesight as well as cerebral lesions (peduncular or other) can result in visual hallucinations 
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2.2.2 Prevention and non-pharmacological interventions. 
BPSD are highly challenging for the patients themselves, their caregivers (both professionals and 
non-professionals), and the other residents in hospital or long-term care facilities. 
A key aspect in managing the BPSD is therefore prevention, which involves avoiding both all 
generally acknowledged triggers or contributors, as well as those that are specific to a given 
patient and which are a corollary of their history and clinical characteristics.  
 
Physical environment 
Basically, a long-term care facility is a surrogate home.  As such, it must offer the residents the 
feeling of being at home, of being free to move about but also to  retire into the intimacy of their 
own bedroom.    Everything should be done not only to allow them to express their needs and 
wishes and use their remaining capacities, but also, when needed, to assist them in the ADL.  In 
short, a facility that adapts itself not only to the needs of its residents as a group, but also to  those 
of each of them as an individual, is expected to find itself facing  less BPSD. 
 
Human environment. 
Admitting someone into specialist residential accommodation means providing them with 
services.  Each professional involved should be aware of their primary commitment, which is to 
preserve or even improve their residents’ quality of life. 
In nursing home, continued education is a key aspect of the organisation of care.  It has been 
shown that “one-shot” training courses are useless, because their effects on daily practice fade 
away quickly (Kuske et al., 2009). In addition, there can be a high  turnover rate in the  teams; 
each newcomer should be trained before taking up their duties, as a means to ensure  consistency 
in the manner in which the whole team works.  
An inherent feature of  institutional accommodation is multidisciplinarity. This term usually refers 
to doctors, nurses and paramedical contributors, which is rather restrictive. Indeed,  everybody, 
from the administrative director to the cooks and maids, should receive the same training and 
adapt their behaviour accordingly when interacting with each other as well as with the residents. 
In order to minimise the severity of the  BPSD, the latter  should be detected early. The systematic 
use of rating scales should be encouraged. 
Familial caregivers should be provided with training as well, not only when the patients are still 
living at home, but also after they have  been institutionalised. Once again, the aim is to ensure 
that their attitude is in line with that of the professional team.  
There are many non-pharmacological interventions available, which are focused  on the patients 
(cognition, emotion, sensory stimulation, ADL, physical activity, communication, environment 
modification, nutrition), the caregivers (continued education for professionals, respite care) or on 
both the patients and the familial caregivers (psychoeducation). The clinical trials that studied 
those approaches are of rather poor quality and heterogeneous, making it difficult to use them as 
support for guidelines. After reviewing the available evidence, the Belgian Health Care Knowledge 
Centre (Kroes et al., 2011) made the following recommendations: 
 
Among all the non-pharmacological treatments for people with dementia, there are sufficient 
scientific data available to recommend the following categories : 
- Support to and training for  informal caregivers, including multiple interventions at home: 
a positive effect was observed on institutionalisation 
- Training for professional caregivers 
- Physical activity program at home or in the institution 
- Cognitive training/stimulation  
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No precise description can be made of the  modalities for administering these treatments  on the 
basis of the studies that have been published. Nevertheless, it has been demonstrated that these 
interventions are more efficient if they 
- are adapted to the patients and their  close circle in order to better address their needs, 
- are followed by well-trained professionals, 
- are provided for a sufficient period of time, with regular contacts in order to produce meaningful 
effects. 
As far as other non-pharmacological interventions are concerned, no formal recommendations 
can be made on the basis of the current data. 
 
2.2.3 Pharmacological intervention 
Psychotropic drugs are extensively administered to patients with dementia and BPSD.  As is the 
case in other guidelines, we argue that  these drugs should not be the first-line response or that, 
if given as an emergency solution, this approach should be very quickly discussed and 
challenged, in light of the analysis of the target behaviour, which includes ruling out any  
intercurrent medical condition and any side effects of  existing medication.  When drugs are used, 
this  should be for  precise indications for which they have been found to be efficient. 
Antipsychotics in AD (Sultzer et al, 2008) have been shown to be superior to placebo against 
hostile suspiciousness (olanzapine and risperidone) and psychosis (risperidone). 
Citalopram is an alternative (Nyth and Gottfries, 1990; Pollock et al. 2002, 2007;Porsteinsson et 
al. 2014): in moderate to severe AD,  it has  an effect on agitation and psychosis that is similar or 
superior to that of risperidone. Whilst citalopram does cause less extrapyramidal symptoms, it  
induces lengthening of the QT interval as well as  a risk of hyponatremia, which require  
monitoring. In a retrospective analysis of the CATIE-AD data, adding  citalopram to antipsychotic 
medication  in a 44-patient sub-group had no effect on delusions and  a questionable effect on 
hallucinations. The effect on irritability and apathy was not significant, although both were down 
by 60% in the  group undergoing treatment (Siddique et al., 2009). 
Patients with DLB did not tolerate citalopram or risperidone, and did not benefit from either (Culo 
et al, 2010).  
Sertraline was compared to low-dose haloperidol in patients with AD, vascular dementia (VaD) or 
mixed dementia and agitation, with similar efficacy (Gaber et al., 2001). 
When added to donepezil, sertraline had no significant effect on NPI, CGI-I or CGI-S scores 
(Finkel et al., 2004). 
Studies were conducted on administering sertraline in cases of depression associated with AD, 
with variable results (reviewed in Henry et al., 2011).  In advanced stages, no difference was 
found to exist with placebo. Patients at a moderate level (MMSE = 17) with major depression 
responded better to the active compound than to placebo with, in addition, a decrease in 
behavioural disturbance and improved ADL.  In mild to moderate cases (MMSE = 21) , a 24-week 
sertraline treatment was not associated with any improvement in mood or non-mood symptoms, 
function or quality of life . 
In a small (n=15) open study on frontotemporal dementia (FTD) citalopram significantly reduced 
the total NPI score, disinhibition, irritability and depression (Herrmann et al. 2012). 
In FTD, other antidepressants were reported to have a significant positive effect on the overall 
NPI score: trazodone, paroxetine, fluvoxamine. However, randomised, controlled trials are 
scarce; in such studies, trazodone was shown to significantly decrease the total NPI score, while 
paroxetine had a non-significant worsening effect (Huey et al., 2006). 
Trazodone was compared to haloperidol in patients with AD and agitation, with a modest effect 
on both medication and a better tolerance to trazodone, the efficacy of which was associated with 
the extent of concurrent mood symptoms (Sultzer 1997, 2001). 
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Trazodone is widely used in patients with dementia and sleep disorder; this practice is based on 
data obtained from  depression studies which were not always focused on older patients, but data 
in dementia are scarce. Trazodone was found to be the most frequently used treatment for sleep 
disorders in community-dwelling AD patients, with the highest proportion of subjective 
improvement (Camargos et al., 2011). In a short-term randomized controlled trial (RCT), 
trazodone administered  at the dose of 50 mg increased the duration of sleep (Camargos et al., 
2014). 
Trazodone is also used as a means to treat anxiety. Again, this use is based on data obtained in 
anxiety disorders, but none of these studies were conducted  with  dementia patients  or even 
elderly patients (reviewed in Bossini et al., 2012). 
Doxepin at doses up to 6 mg is a selective histamine-1 receptor antagonist, therefore free of the 
side effects due to muscarinic and alpha-1 adrenergic receptor blockade. Studies in elderly 
patients showed   a significant effect on sleep continuity and duration but not on sleep latency, 
efficacy beyond  12 weeks and no rebound after withdrawal (reviewed in Rojas-Fernandez, 2014). 
Memantine has been shown to prevent agitation/ aggressiveness, irritability / liability, night-time 
behaviour and to reduce delusions, agitation/ aggressiveness and disinhibition in patients with 
moderate to severe AD(Gauthier et al., 2008). This observation was based on pooled data from 
several RCT where behaviour was a secondary outcome.  They were not confirmed by an RCT 
focused on agitation in moderate-to-severe AD(Fox et al, 2012). 
There is no evidence that  acetylcholinesterase inhibitors (AChEI) have an effect on BPSD (Seitz 
et al., 2013). 
In Parkinson’s disease dementia and Lewy-body disease, rivastigmine had a significant effect on 
the NPI-10 score; hallucinations were less frequent with AChEI, though this effect was not 
significant (Rolinski et al., 2012). 
In one small (n=12) open study on FTD, donepezil increased disinhibition and compulsive 
behaviour. 
There is no recognized indication for administering benzodiazepines to patients with dementia.  
However, they are widely prescribed to patients with BPSD, in combination with antipsychotics in 
40% of cases. While two studies found that lorazepam and alprazolam can  reduce agitation in  
AD, no improvement of sleep quality was shown to occur with benzodiazepines.  Benzodiazepines 
induce a 2.8 times higher deterioration rate over a 12 month-period and hasten death.  
Benzodiazepine users are 5.8 times more likely to experience falls (reviewed in Defrancesco et 
al., 2015). 
Although no study has demonstrated the validity of this approach, lorazepam is often used in case 
of acute agitation in patients with Lewy-body dementia or Parkinson’s disease dementia. 
Among mood stabilizers, carbamazepine (CBZ) has the most robust evidence in support of its  
efficacy on BPSD global scores, aggression, hostility, and possibly agitation; there has been no 
face-to-face study comparing CBZ to antipsychotics. RCTs and meta-analyses did not provide 
any evidence in support of the efficacy of valproate.  In one RCT with topiramate, this compound 
reduced overall BPSD scores and agitation, without there being any significant difference with 
risperidone; it must be pointed out that topiramate has been reported to cause cognitive 
impairment in young patients with epilepsy.  One RTC was carried out with oxcarbazepine and it 
showed negative results.  There is no RCT or meta-analysis on gabapentine, lamotrigine or lithium 
carbonate use in BPSD (reviewed in Yeh and Ouyang, 2013). 
Despite the lack of RCTs on clonazepam in rapid eye movement sleep behaviour disorder (RBD: 
Howell and Schenck for a review), there is a consensus on the efficacy of clonazepam, with up to 
90% of patients responding to doses of 0.5 to 1 mg. 
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2.2.4 Specific behaviours and symptoms 
Strolling is frequently observed in institutionalised patients. Most often, it is caused by an 
environment that is perceived as stressful.  In the early hours or days of a patient’s stay, this  can 
be compared to the behaviour we all display when arriving at a holiday destination: we drop our 
suitcases, go out and walk around to familiarize ourselves with our new environment.  The patient 
is just trying to find landmarks. This can be disturbing for other patients or residents, because it 
implies that all  the doors will be opened  and that, in many cases, the rooms will be explored.  
This behaviour cannot be treated by means of medication. Moreover, preventing patients from 
behaving like this  is not only liable to result in agitation that can become aggressive, but, most 
importantly, will  prolong this type of behaviour, because it is a necessary step in their integration 
process. Escorting them, explaining what the different rooms are for and introducing the other 
patients / residents to them is both preferable and energy-saving: nobody will be distressed. 
When this behaviour continues after the first days of their stay, it usually reflects anxiety about 
the environment, either human (other residents, unusual behaviour of the team, loss of contact 
with their family, real or due to memory impairment, family conflicts expressed during visits…) or 
material (changes in furniture, in ward décor, less or more light …). 
Drugs such as serotonin-specific reuptake inhibitors (SSRI) antidepressants and antipsychotics 
induce akathisia, i.e. the inability of staying without moving, which can be mistaken as strolling. 
 
Exit-seeking is seen in middle-stage dementia, since it requires the ability to plan an action and 
to carry it out.  The motivation is either to leave the facility for a specific purpose  (“elopers” want 
to go to work, to be at home when the children return  from school, to prepare  the meal…) or to 
escape from an unfriendly environment (“runaways”).  When residents  have  decided to leave, it 
is useless to try to convince them  that they  may not do so: this attitude usually upsets them  and 
sometimes triggers aggressive behaviour from them. In elopers, exit –seeking behaviour can be 
avoided by engaging them in the kind of activities they think they have to carry out, by  validating 
their wish to leave, letting them speak about their goal and then  trying to engage them in a close 
activity after having explained that, unfortunately, there is currently no transportation available.  
The reason why runaways feel uncomfortable should be understood and corrected.  Here too, 
validation is the first step: it will help understand the reason why they feel uncomfortable and 
provide an opportunity to make a suggestion  (meeting other people, listening to a song, seeing 
a video of loved ones, eating, drinking…) that can correct this feeling.  In the Canadian resting 
home “carpe diem”, when caregivers see a resident crossing the portal, they offer to walk with 
them, which gives them time for validation. 
 
Wandering is particularly distressing for familial caregivers. The questions to address are the  
same as in institutions. In addition, many patients want to “go back home”, which, again can reflect 
a feeling of discomfort but also a wish to be in the home where they lived when they were young, 
with their parents and siblings.  Basically the attitude is the same as above and consists of 
validation, with the difference that, at home, there is no architectural limit to wandering.  The 
“Carpe Diem” approach is probably the best one. 
 
Apathy (reviewed in Dujardin, 2007 and Cipriani et al., 2014) has been defined  as “an observable 
behavioural syndrome consisting of a quantitative reduction of voluntary (or goal-directed) 
behaviours”.  It is the most prevalent behavioural change in patients with AD  (19%-92%), where  
it appears early and increases as the  disease progresses, as well as in the behavioural variant 
of frontotemporal lobe dementia (62%-89%). It is very frequently found  in Parkinson’s disease 
(24%) but is much more common in Parkinson’s disease dementia (54%), progressive 
supranuclear palsy, Huntington’s disease (21%-60%) and vascular dementia, with a higher 
prevalence in small-vessel dementia (64%) than in large-vessel (54%) dementia. 
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A differential diagnosis must be made with depression and with delirium.   
The main difference with depression is the lack of dysphoria. However, these two illnesses share 
common symptoms that can account for the  overdiagnosis of depression in patients who are 
unable to express their feelings (Table 1). 
 
Table 1 : Signs and symptoms in apathy and depression 
Apathy-characteristic Shared Depression-
characteristic 
Lack of motivation Loss of interest Sadness 
Lack of initiative Psychomotor slowness Suicidal ideation 
Blunted emotional responses Fatigue, loss of energy Worthlessness 
Indifference Hypersomnia Feeling of guilt 
Social withdrawal Lack of insight Pessimism, gloominess 
Lack of perseverance Hopelessness Anorexia 
 
Although the hypoactive form of delirium can look like apathy, its acute onset, fluctuating course 
and other features make it rather easy to differentiate both conditions. 
Finally, apathy has to be distinguished from the effect of sedative drugs, particularly neuroleptics. 
Despite its high prevalence, there have been few studies on the treatment of apathy. 
Non-pharmacological intervention focused on educating caregivers about  the meaning, nature 
and pathophysiology of apathy is certainly a valuable, necessary first step. The aim is  to avoid it 
being misinterpreted  as laziness or opposition..  The caregiver can then be  trained to stimulate 
and structure the patient’s daily activities.  Therapeutic activities have been found to be  the only 
type of intervention on which enough high-quality studies have been conducted. 
The problem with pharmacological interventions is that apathy was a secondary outcome 
measure in most studies. Some improvement has been obtained with psychostimulants 
(methylphenidate, dextroamphetamine), dopaminergic agonists (pergolide and bromocriptine) 
and there has been a case report describing a  response to bupropion.  There are non-randomised 
controlled trials (15 revealing a positive effect, 3 showing no benefit) and observational studies 
with controls (11 positive, 7 negative) that demonstrate  that acetylcholinesterase inhibitors are 
beneficial in apathy.  Memantine in severe dementia of various types had an effect on apathy in 
two RCTs; an open-label study in FTD showed no effect.  Antidepressants do not improve apathy; 
on the contrary, serotonin specific reuptake inhibitors have been associated with indifference. 
 
Depression 
Along with apathy, depression is one of the most frequent BPSDs. 
The diagnosis of depression is difficult to make in elderly patients, because the meaning of 
complaints and signs (pain, anorexia, sleep impairment) can be blurred by concomitant diseases.  
In addition, patients with dementia are less able to express their feelings and display signs such 
as apathy or tears that erroneously suggest depression. 
Diagnostic criteria that  reduce the importance of verbally-expressed symptoms and include 
irritability and social withdrawal have been proposed for depression in AD (Table 2, Olin et al., 
2002). 
The Cornell Scale for depression in Dementia (Table 3 Alexopoulos et al., 1988) is widely used 
to quantify depression and even to diagnose it, since cut-off scores have been proposed for the 
diagnosis of depression. 
Even with these tools the task remains difficult.  It is safe to consider that any rapid (not abrupt, 
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Table 2 :   Provisional diagnostic criteria for depression in AD 
Three or more of the following criteria over the same 2-week period. They must represent a 
change from previous functioning: 
Depressed mood (sad, hopeless, discouraged, tearful) 
Decreased positive affect or pleasure in response to social contacts and 
activities 
Social isolation or withdrawal 
Disruption in appetite 
Disruption in sleep 
Psychomotor agitation or retardation 
Irritability 
Fatigue or loss of energy 
Worthlessness, hopelessness or excessive guilt 
Recurrent thoughts of death or suicidal ideation 
All criteria are met for dementia of the Alzheimer type 
Symptoms cause distress or disruption in functioning 
Symptoms do not occur exclusively during delirium 
Symptoms are not due to substances (medications or drug abuse) 
 
Table 3:  Cornell Scale for Depression in dementia 
Mood-related signs 
Anxiety: anxious expression, ruminations, worrying 
Sadness: sad expression, sad voice, tearfulness 
Lack of reactivity to present events 
Irritability: annoyed, short tempered 
Behavioural disturbance 
Agitation: restlessness, handwringing, hair pulling 
Retardation: slow movements, slow speech, slow reactions 
Multiple physical complaints (rate 0 if gastrointestinal symptoms only) 
Loss of interest: less involved in usual activities (score only if change 
occurred acutely, or in less than one month) 
Physical signs 
Appetite loss: eating less than usual 
Weight loss: (rate 2 if greater than 5 pounds in past month) 
Lack of energy: fatigues easily, unable to sustain activities 
Cyclic function 
Diurnal variation of mood: symptoms worse in the morning 
Difficulty falling asleep: later than usual for this individual 
Multiple awakenings during sleep 
Early morning awakening: earlier than usual for this individual 
Ideational disturbance 
Suicidal: feels life is not worth living 
Poor self-esteem: self-blame, self-depreciation, feelings of failure 
Pessimism: anticipation of the worst 
Mood congruent delusions: delusions of poverty, illness or loss 
 
Scoring system 
A= Unable to evaluate; 0 = Absent; 1 = Mild to intermittent; 2 = Severe 
score greater than; 12 = Probable depression 
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Despite its high prevalence in dementia, depression treatments have not been extensively 
studied.   The studies included in meta analyses have  identified various outcomes for SSRIs and 
mirtazapine, probably because they used different diagnostic criteria and outcome measures 
(reviewed in Kales et al., 2015). It follows that we have no firm recommendation to make regarding 
the choice of antidepressant. Given this uncertainty about their efficacy, regardless of the 
antidepressant used, the adverse effects and the risk/benefit ratio must be monitored carefully.  
 
According to Cohen-Mansfield et al (1989), a distinction may be drawn between different types of 
agitation, viz. verbal non-aggressive, physical non-aggressive, and aggressive, each of which 
has  distinct causes and requires specific approaches (Table 4). 
Rating scales such as the Cohen-Mansfield Agitation Inventory or CMAI (Cohen-Mansfield et al., 
1989), the NPI (Cummings et al., 1994), or the Behavioural Pathology in Alzheimer’s Disease 
(BEHAVE-AD; Reisberg et al.,1987) rating scale are used to quantify agitation.  However, until 
recently, no definition or diagnostic criteria were available for agitation in syndromes with cognitive 
impairment.  The International Psychogeriatric Association set up an Agitation Definition Working 
Group, which provided a provisional consensus definition (i.e. one that is accepted by a majority 
of stakeholders, viz. 68 to 88%, depending on the definition component under consideration.)  
(Cummings et al.,  2015): 
(1) the behaviour occurs in patients with a cognitive impairment or dementia syndrome; 
(2) patients exhibit behaviour consistent with emotional distress; 
(3) patients display excessive motor activity, verbal aggression, or physical aggression; 
(4) evidencing the patients’ behaviour causes excess disability and is  not solely attributable to 
another disorder (psychiatric, medical, or substance-related). 
In line with Cohen-Mansfield’s approach, an important aspect of this definition is that  agitation is 
looked upon as the expression of the patient’s upset or distress.   This definition also recognises 
that agitation can take different forms, which suggests that t different approaches are needed.  
Finally, this behaviour induce excess disability, which again focuses on the patients as the primary 
sufferers from their state. 
 
A recent review of RCTs using non-pharmacological approaches (Livingston et al., 2014) found 
evidence in support of the efficacy of: 
- activities and music therapy in care homes, though no  information is provided on long-term 
effects or nor is there any evidence concerning  people with severe agitation ; 
- person-centred care and dementia care mapping training of care home paid staff with 
supervision in severe agitation with mid- and long-term persistence of efficacy.  
There was no evidence in support of the efficacy of  these approaches in other settings. 
 
No evidence was found in support of the  efficacy of  light therapy (which was found to be liable 
to  worsen agitation in one study), aromatherapy, and training family caregivers in behavioural 
management therapy. 
 
For some interventions, there was insufficient evidence to allow a definitive recommendation: 
physical exercise, training caregivers without supervision, simulated presence. 
 
As discussed in detail above, several classes of drugs display a limited effect on different aspects 
of agitation:  antipsychotics, the antidepressants citalopram, sertraline and trazodone, CBZ . 
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Table 4:.  Possible determinants of agitation 
Behaviour Strongly linked with Treatment 
Verbal, non-
aggressive 






Poor sleep quality 
Improve staff behaviour 
Antidepressants 
1. identify and correct 
environmental causes 






Poor sleep quality 





1. identify and correct 
environmental causes 
2. SSRI or trazodone in small 
doses 
Aggressive Quality of interpersonal relationships 
Verbal / non-verbal communication 
Depression 
Poor sleep quality 
Delirium 
Improve staff behaviour 
Improve staff behaviour 
Antidepressants 
Causal 
Causal; prn haloperidol if 
dangerous 
 
Delusions may be part of depression. In this case, they are congruent with mood (worthlessness, 
guiltiness, ruin…). They respond to antipsychotics given in association with antidepressants and 
are still an indication for electroconvulsive therapy even in patients with dementia. If they are the 
consequence of hallucinations, this behaviour should be analysed first (see below). They can also 
be the consequence of vision or, more commonly, of hearing impairment leading to the 
(erroneous)  interpretation of other peoples’ attitudes or conversations; proper correction of the 
deficit must be carried out first. 
 
Hallucinations are often the consequence of impaired perception  (Charles Bonnet syndrome for 
visual impairment, or its equivalent for hearing). Unfortunately, it is not always possible to correct 
the deficiency; moreover, antipsychotics are rather seldom efficient. The latter should therefore 
be initiated only if these hallucinations cause suffering to the patient or if they induce delusional 
behaviours that put them or  others in danger/ If  they are given to the patient, the benefit / harm 
balance should be carefully and repeatedly estimated.  Peduncular hallucinosis is a condition that 
was described in 1922 (Lhermitte, 1922) and is caused by lesions located in a region that 
stretches roughly from thalamus to the emergence of the fifth cranial nerve. Some effect has been 
obtained with olanzapine (Spiegel et al., 2011), but also with fluoxetine (Gilles et al., 1996).  
Hallucinations are one of the main symptoms of Lewy-body and of Parkinson’s disease dementia, 
in which antipsychotics are prohibited (except for clozapine). Rivastigmine has been claimed to 
be an alternative (Rolinski et al., 2012) and pimavanserin, a 5HT2A inverse agonist, is promising 
(Schrag et al, 2015). 
 
Sleep disorders are common in dementias. They are exhausting for familial caregivers and are 
therefore  a major cause of institutionalisation. They are also difficult to manage in hospitals or 
nursing homes, where they induce inappropriate, toxic, ineffective drugs administration. Again, 
an analytical approach is the key to appropriate treatment (Table 5). 
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Table 5 :  Sleep disorders subtype: possible causes and treatments 
Subtypes Possible causes Treatment 
Long sleep latency Bedtimes don’t line up with the  
patient’s rhythm 
Noisy environment 
Low diurnal physical activity 
Anxiety 
Inquire about patient’s rhythm 
and respect it 
Correct 
Increase 
Bedtime ritual, milk, herbal 
tea, massage… 
Awakenings Environment (blood drawing at 4 
am) 
Low daylight exposure 
Low diurnal physical activity 
Gastro-oesophageal reflux 
Dyspnea (CHF, COPD) 
Pain 
Cramps: idiopathic, arteriopathic, 
iatrogenic (e.g. AChEI) 
Incontinence 
 
Periodic leg movements 
SAS 





Bed in armchair position / 
treat 
Treat 
Treat / modify Rx 
 









Environment (diurnal atmosphere 
outside rooms) 




1. Allow free walking, 
drinking, eating 
2. Gentle contention (2) 
3. Hypnotic (doxepin 3-6 mg) 
Agitation Delirium 
 
REM sleep behaviour disorder 
Causal. Prn haloperidol if 
dangerous 
Clonazepam 
Early awakening Early bedtime 







(1): Awakenings in patients with dementia are almost systematically followed by activation, 
simply  because they are not aware that it is still night-time and that they should sleep.  Bright 
lights in the lobby, noise, people working reinforce this unawareness. In the Canadian nursing 
home “Carpe diem”, lights are dimmed and night caregivers wear nightwear, which makes it 
easy to convince patients that it’s still time to sleep  
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2.2.5 Conclusions 
The current approach for behavioural and psychological symptoms in patients suffering from 
dementia is highly ineffective and has a high harm / benefit ratio.  The reasons are that it is driven 
by fear, is more targeted towards  caregiver protection than it is towards patient comfort, aims at 
making patients adapt to an environment that is primarily organised for caregivers, and 
inappropriately responds to various symptoms by administering sedative drugs without 
understanding the causes behind those symptoms. 
The alternative is to adopt an analytical view. Dissecting these common behaviours and 
symptoms allows to define treatment attitudes that provide a specific response to precise 
indications. Educating caregivers to this approach will enhance their confidence, reduce  fear 
reactions and allow them to pay attention to patients’ feelings and often suffering.  The enhanced 
efficacy and lower toxicity of the treatments will reinforce their satisfaction.  
 
3 Ethical issues 
The ALCOVE project has formulated recommendations about the rights, autonomy and dignity of 
people with dementia, which mainly concern two areas:   
- competence assessment 
- advance directives  
 
The SHC endorses the various recommendations made by the ALCOVE project regarding 
competence assessment3, but insists on the fact that these competences cannot be assessed in 
a dichotomous manner, but as a subtle continuum.  In addition, it is important to respect people's 
gradual ability for self-determination. This can range from the full ability to decide and consent in 
the early stage of dementia to a very tenuous ability to communicate their wishes regarding daily-
life experiences at a very advanced stage. 
In addition, the SHC advises that it should be possible to conduct a neuropsychological 
competence assessment at certain "turning points" of the disease.  
 
Regarding the recommendations for advance directives, it should be pointed out that Belgium is 
one of the countries in which they already have a strong legal status (they are binding as regards 
negative wishes) (Andorno, 2008), which means that they have a significantly more extensive 
impact than in other countries, such as France.   
                                               
3  [1] A person diagnosed with Alzheimer's disease or dementia should not automatically be considered unfit to exercise 
their right to self-determination.  
[2] When the person living with Alzheimer's disease is not able to make decisions on their own, the proxy or 
representative appointed by them (for future protection) should be involved.  
[3] The competences must be assessed on a case-by-case basis, this assessment must be repeated for all major 
decisions regarding the treatment or care provided.  [WP7.3] 
[4] When assessing an individual's  competences, contextual factors must be considered, including medical, 
psychological and social factors. [WP7.4] 
[5] Assessing a person's ability to make decisions about the care and treatment provided to them must be performed 
by a trained and qualified healthcare professional.  
[6] Further research is necessary on the development and validation of effective and practical assessment tools, 
especially for people with a progressive cognitive disease such as Alzheimer's disease. [WP7.6] 
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In Belgium, the main concerns are therefore the following: (1) that of transmitting the information 
collected in order to ensure that it is available at the right time as well as (2) the way in which the 
conversation is conducted (when, how, what is taboo, with whom, updating ....). How is the 
information collected and what is done with it ?  
 
Thus, the SHC wishes to put the main focus on the first recommendation made by the ALCOVE 
project, viz. that "Advance directives should be part of the broader context of advance care 
planning."   
Indeed, the SHC insists on the fact that advance directives must be placed within a broader 
context and that their importance must be relativized. Thus, they reflect a certain image we have 
of human beings, but this image is not an absolute one.   
Today, the fact that advance directives are being considered is strongly influenced by an 
autonomous and cognitivist image of human beings.  This means that we look upon human beings 
as individual (independent) and rational entities with the ability to fully determine their own wishes.  
Based on such an individualistic image of the human being, it is possible to draw the following 
conclusions regarding advance directives: 
-  Respecting the individual's autonomy is, in this context, considered the overriding 
principle. Considerable attention is given to what the individual considers to be their will. 
- These wishes can be determined rationally. In other words, expressing one's own wishes 
constitutes a rational and solitary activity.  
- The wishes expressed by an individual are not subject to change and may be considered 
as absolutely certain.  
- The wishes expressed in an advance directive are quite clear to the physician  and 
achievable (cf. an   order form) 
- The wishes expressed by someone who is able to communicate their desires ('then self') 
always have priority over the 'wishes'  expressed by someone who is unable to do so ('now 
self') in the face of their current experiences and perceptions. 
An increasing amount of criticism is being issued on this cognitivist and individualistic approach 
to advance directives. This criticism is based on an integral image of human beings that takes 
seriously the relational solidarity between human beings and their actual experiences and 
perceptions. Based on such an integral image of human beings, it is possible to draw the following 
conclusions regarding advance directives:  
- Writing down one's wishes is a difficult task that requires an effort that is cognitive, 
emotional as well as relational. It is best that human beings establish a dialogue with 
others from the start (family members, general practitioner, ...) in order to determine their 
own wishes gradually and write them down.  It is also preferable to appoint someone who 
will be able to provide an oral explanation of the wishes that have been thus written down. 
- Interpreting "wishes on paper" is a difficult task and requires a cognitive, emotional and 
relational effort from the caregiver. 
- It is usually not that easy to deduce the wishes of the patient from an advance directive. 
On the contrary:  determining these wishes usually requires interpreting what is written in 
the advance directive. The content of the advance directive must therefore be interpreted 
through dialogue between all those concerned with the patient. 
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- It should be borne in mind that people's wishes can evolve constantly, even when they 
have become unable to express them. 
- People can also adapt to new situations that they initially experienced as highly negative. 
- The variability of people's wishes as well as their ability to adapt to negative situations and 
their right to express contradictory and ambiguous views about end-of-life care, have 
meant that we must fully take into account the wishes of the ‘now self' who is unable to 
express their own wishes and not only with those written down in the advance directive by 
the 'then self'.  Indeed, these two identities should always be taken into account: the 
person who wrote down the advance directive, and the person with dementia, to whom 
they apply (whilst being careful to abide by the conditions of validity set by law, which, 
among other things, differ depending on whether the advance directive concerns 
euthanasia or treatment). The current perceptions/experiences of those unable to express 
their own desires must be taken seriously.  
Starting with an integral image of human beings that takes both the wishes of the 'then self' as 
well as those of the 'now self' seriously, we call for the integration of the advance directive into 
the advance care planning model. This model ensures that there is a continuous communication 
process between the patients and all those who, in a positive way, are concerned with them 
(family members, caregivers  ...). Such a context allows for a growing awareness of the care that 
is best suited for end-stage patients.  
 
It follows that advance care planning is a model that provides good support to communication 
between all stakeholders. It also allows taking into account the context, which is all too often 
obscured in advance directives, but often fluctuates. It is indeed more comprehensive than the 
advance directive because it conveys the wishes for the patient's future existence, and has a 
much greater effect on the quality of the end of life. In contrast, the advance directive only 
concerns the medical sphere, the care provided.   
Flanders is currently working on practical guidelines on advance care planning (see  
http://www.palliatief.be/template.asp?f=k_en_e_vroegtijdige-zorgplanning.htm and  
http://www.pallialine.be/template.asp?f=welkom.htm). 
Thus, advance directives should not be looked upon as an end in themselves, but rather as a 
means to discuss the future. The main purpose is to promote dialogue with the person concerned 
in order to have a shared understanding of their wishes, priorities and preferences, so as to 
strengthen their rights and respect their autonomy whilst protecting them and taking into account 
their environment. It is especially the dialogue that is important when drawing up advance 
directives and implementing them. Also, a distinction should be drawn between the dialogue 
process that aims at understanding these people's wishes and the product of this dialogue, which 
should not necessarily result in advance directives.  
It follows that another recommendation made by the ALCOVE project is of paramount importance, 
viz. the fact that "Advance directives are preferably  accompanied by a personal statement 
of values containing information about what is important and meaningful in the life of the 
person who has drawn up the directive.” 
 
Given the fact that it is virtually impossible to describe all possible future scenarios in an advance 
directive, the latter should record the broad framework of the patient’s values. This broad 
framework of values should clearly reveal how the patients look upon their own lives and 
vulnerability.   
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It should therefore contain a set of information on the patients, their lives, values but also aspects 
of their everyday existence (intimacy, sexuality, etc....) that are important for their quality of life.  
This information can help healthcare providers and relatives to understand what kind of end-of-
life care is best suited for the patients.  
This can also justify encouraging advance care planning (ACP) independently of any context of 
dementia and diagnosis (especially of dementia or Alzheimer's disease). 
Moreover, the ALCOVE project also issues the following recommendation: '"It is important to 
advise persons living with dementia of the possibilities of advance care planning and the 
use of advance directives whilst they still have the necessary competence and mental 
capacities to make use of them. Therefore, the importance of a timely and disclosed diagnosis 
needs to be underlined. Nevertheless, a sensitive approach is necessary, taking into 
consideration that not all persons are prepared to decide about their future.”  
 
Elderly people need to be correctly advised about ACP and advance directives.  In this context, it 
is paramount to avoid or correct erroneous assumptions or errors regarding the implementation 
of the advance directive. Hence, it is important that elderly people understand the relationship 
between advance directives and euthanasia.  The elderly should be advised about the meaning 
of all medical decisions regarding the end of life (e.g. not initiating/ stopping medical treatments 
that prolong life; palliative sedation; fight against pain, euthanasia ...). They must receive correct 
information about the scope of advance directives in terms of euthanasia. This item could, for 
example, be a fixed component in the care diagnosis.  
 
This also requires a great deal of transparency (especially as regards the diagnosis) in the 
relationship between doctor and patient. Thus, heed must be taken to promote it.   
 
But it should be borne in mind that giving too much importance to these advance directives could 
provide a false sense of security with respect to what will happen in the future because eventually, 
their impact will  often be but limited (if  they have no legal value). 
 
This is also in line with two other recommendations of the ALCOVE project that the SHC considers 
crucial, and which must be repeated systematically, viz. "Although the use of advance 
directives should be promoted, nobody can be forced to make up an advance directive" 
and "The person's current attitude towards a certain treatment or a care intervention - 
ascertained feelings, desires and wishes - should always be taken into account, even if 
there is an advance directive or a designated proxy, since there can be major changes in values 
and preferences between the time when persons complete their advance directive and when it 
comes into effect".  
 
Indeed, no-one can be compelled to think about the end of their life and plan end-of-life care in 
advance.  Patients may have good reasons to put complete trust into their relatives and caregivers 
for their end-of-life care.  Thus, the aim is not to write an advance directive, but to seek to take 
into account the views of the patients as much as possible. Hence, the various possibilities for 
achieving this goal must be assessed.   
 
In addition, there should always be the possibility of reviewing the advance directives, which 
should not be looked upon as static documents.   
 
Thus, the mere existence of advance directives does not suffice, and the manner in which they 
are used should also be considered. Indeed, it is often difficult to interpret information prior to 
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taking a decision. It follows that the SHC also abides by the recommendations made by the 
ALCOVE project as regards the concerns in terms of the quality and professional training that are 
required to implement the advance directives :  
 
- "Proper models and good practices specifically oriented towards people living with 
dementia need to be implemented, further developed and disseminated".   
- "Doctors and other healthcare professionals involved in the care of people living 
with dementia should be properly trained in advance care planning and the use of 
advance directives." 
Elderly people, their relatives and caregivers should be advised about the importance of early 
communication about end-of-life care.   
There is also a need to raise awareness and provide training at various levels.  
The training and continued training for caregivers should mainly focus on the communicative and 
interdisciplinary nature of advance care planning.  Nursing and medical students should receive 
common training on this subject.  Nursing and medical students should be introduced to the ethical 
and legal aspects of end-of-life care as well as to the use of advance directives.   
 
In order to gain a better understanding of the factors that do or do not facilitate the initiation of 
advance care planning, reference can be made to the systematic review of Van der Steen et. al 
(in press). These authors have shown that a broad variety of factors are involved.  Family-related 
factors seem to be the most important, followed by the healthcare professional's attitude and 
factors related to the patient's health. The continuity of care and the healthcare system also seem 
to have an effect on whether or not an advance directive is initiated.   
 
Finally, care must be taken not to overproceduralise the drawing up of advance directives, as this 
practice must not be reduced to rigid theoretical models. Still, it is necessary to set up models, 
especially in institutions, that are tailored to the population. Specific care settings and patient 
groups require specific ACP models.  
Nursing homes, health centres and hospitals must develop a written ethics policy and guidelines 
for clinical practice concerning medical decisions for the end of life (e.g. not initiating/stopping life-
prolonging medical treatment, palliative sedation, fight against pain, euthanasia....) as well as 
advance directives and ACP.  
 
Moreover, the Fondation Roi Baudoin supports various projects pertaining to the implementation 
of ACP for people suffering from dementia (see also the report Penser plus tôt ... à plus tard.  
Projet de soins personnalisé et anticipé: Réflexions sur son application en Belgique avec une 
attention particulière pour le déclin cognitif" sur http://www.kbs-
frb.be/publication.aspx?id=295125&langtype=2060). 
 
Perhaps advance care planning should be encouraged before the diagnosis is made: as early as 
during the first consultation, of for the population in general, from a certain age? The advantage 
of making such planning normal would be that this would reduce the stigma.  GP’s should also be 
made aware of this issue.   
The "Federatie Palliatieve Zorg Vlaanderen" has developed guidelines on advance care planning, 
and the Fondation Roi Baudoin is in turn looking into the adaptations that need to be made for 
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III CONCLUSION  AND RECOMMENDATIONS 
Dementia is an issue that has a human, ethical and societal component. It affects not only the 
patients, but also their families, professionals from various disciplines, and society as a whole. It 
is also an issue that evolves rapidly.  Whilst there is no curative treatment available to date, action 
can be taken as regards the quality of life of the patients and their families.   
In order to do so, it is necessary improve the information provided and  promote expert knowledge, 
multidisciplinarity and interdisciplinarity as a means to ensure coordination between all of those 
concerned as well as the continuity of care.  
Hence, the SHC advises that action be taken at three levels:   (1) promote teamwork in specialized 
centres, (2) provide better training to all healthcare professionals, (3) provide better information 
to the public on this illness.  
 
1) Promote expertise, multidisciplinarity and interdisciplinarity 
Dementia is a complex issue that affects many areas and on which knowledge is evolving rapidly. 
It could therefore be useful and interesting to set up training for medical consultants on dementia, 
as is already the case for palliative care, as a means to ensure that the best possible primary care 
is offered. Thus, the GP plays a valuable role in the shared care provided in cooperation with the 
medical specialist. 
As regards second-line care, teamwork in diagnostic centres should also be strongly encouraged, 
be it only in terms of the quality of the diagnoses.  
 
2) Improve the information provided to all healthcare professionals both in terms of detection 
as well as of daily care.    
As part of their initial and continued training, physicians and other healthcare professionals 
(especially those providing primary care) should be made aware of the significance of this issue 
as well as of the solutions that may be considered, potential tools to detect the first signs and 
various kinds of treatment that are available and/or need to be invented on a case-by-case basis.   
In this regard, it seems useful to provide for training curricula on dementia.  They also need to 
include the specificity of early-onset dementia, given the fact that the signs are not always 
recognised in time by healthcare professionals.   
Lifelong learning for professionals in dementia care is preferable above one shot course of one 
day and has to be framed into a whole dementia policy of the institution 
When desired and possible,  the patient's staying at home should be facilitated by improving the 
access to home care, providing better information to carers and those close to the patients and 
improving the cooperation between the latter and the  (medical, legal, psychosocial) services.   
In addition, all these interventions with these vulnerable patients mean that one has to be aware 
that there is a risk of potential adverse effects.  It follows that all steps taken require prior ethical 
review.  
  
3) Providing better information to the public  
Preventive measures make it possible to act on environmental factors (e.g. inactivity). It is crucial 
to provide proper information on this subject to the whole of society. The latter should have a 
more accurate notion of what cognitive and behavioural disorders are, so as to enable people to 
pick up on the signs in time. Finally, providing correct and proper information to the public is also 
very important as means to fight against the all too frequent stigmatisation of people with 
dementia.    
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All experts joined the working group in a private capacity. Their general declarations of interests 
as well as those of the members of the Committee and the Board can be viewed on the SHC 
website (site: conflicts of interest). 
 
The following experts were involved in drawing up and endorsing this advisory report. The working 
group was chaired by DE MOL Jacques; the scientific secretary GERARD Sylvie. 
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About the Superior Health Council (SHC) 
 
The Superior Health Council is a federal advisory body. Its secretariat is provided by the Federal 
Public Service Health, Food Chain Safety and Environment. It was founded in 1849 and provides 
scientific advisory reports on public health issues to the Ministers of Public Health and the 
Environment, their administration, and a few agencies. These advisory reports are drawn up on 
request or on the SHC's own initiative. The SHC aims at giving guidance to political decision-
makers on public health matters. It does this on the basis of the most recent scientific knowledge. 
 
Apart from its 25-member internal secretariat, the Council draws upon a vast network of over 500 
experts (university professors, staff members of scientific institutions, stakeholders in the field, 
etc.), 300 of whom are appointed experts of the Council by Royal Decree. These experts meet in 
multidisciplinary working groups in order to write the advisory reports. 
 
As an official body, the Superior Health Council takes the view that it is of key importance to 
guarantee that the scientific advisory reports it issues are neutral and impartial. In order to do so, 
it has provided itself with a structure, rules and procedures with which these requirements can be 
met efficiently at each stage of the coming into being of the advisory reports. The key stages in 
the latter process are: 1) the preliminary analysis of the request, 2) the appointing of the experts 
within the working groups, 3) the implementation of the procedures for managing potential 
conflicts of interest (based on the declaration of interest, the analysis of possible conflicts of 
interest, and a Committee on Professional Conduct) as well as the final endorsement of the 
advisory reports by the Board (ultimate decision-making body of the SHC, which consists of 40 
members from the pool of appointed experts). This coherent set of procedures aims at allowing 
the SHC to issue advisory reports that are based on the highest level of scientific expertise 
available whilst maintaining all possible impartiality. 
 
Once they have been endorsed by the Board, the advisory reports are sent to those who 
requested them as well as to the Minister of Public Health and are subsequently published on the 
SHC website (www.shc-belgium.be). Some of them are also communicated to the press and to 
specific target groups (healthcare professionals, universities, politicians, consumer organisations, 
etc.). 
 
In order to receive notification about the activities and publications of the SHC, please contact: 
info.hgr-css@health.belgium.be. 
 
 
 
